Loading clinical trials...
Loading clinical trials...
A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Idiopathic Pneumonia Syndrome Following Allogeneic Cell Transplantation (BMTCTN0403)
Conditions
Interventions
Etanercept
Placebo plus corticosteroid
Locations
12
United States
University of Florida College of Medicine (Shands)
Gainesville, Florida, United States
Indiana University Medical Center
Indianapolis, Indiana, United States
Johns Hopkins University
Baltimore, Maryland, United States
DFCI/Partners Cancer Center
Boston, Massachusetts, United States
University of Michigan Medical Center
Ann Arbor, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Start Date
August 1, 2007
Primary Completion Date
June 1, 2010
Completion Date
July 1, 2013
Last Updated
November 1, 2021
NCT07428759
NCT06743529
NCT07409727
NCT06966284
NCT06950294
NCT06494072
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions